Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage chemotherapy (which was followed by high-dose therapy and autologous stem-cell transplantation in pati...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2022-02, Vol.386 (7), p.640-654
Hauptverfasser:	Locke, Frederick L, Miklos, David B, Jacobson, Caron A, Perales, Miguel-Angel, Kersten, Marie-José, Oluwole, Olalekan O, Ghobadi, Armin, Rapoport, Aaron P, McGuirk, Joseph, Pagel, John M, Muñoz, Javier, Farooq, Umar, van Meerten, Tom, Reagan, Patrick M, Sureda, Anna, Flinn, Ian W, Vandenberghe, Peter, Song, Kevin W, Dickinson, Michael, Minnema, Monique C, Riedell, Peter A, Leslie, Lori A, Chaganti, Sridhar, Yang, Yin, Filosto, Simone, Shah, Jina, Schupp, Marco, To, Christina, Cheng, Paul, Gordon, Leo I, Westin, Jason R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Age Aged Aged, 80 and over Antineoplastic Agents, Immunological - adverse effects Antineoplastic Agents, Immunological - therapeutic use Autografts B-cell lymphoma Biological Products - adverse effects Biological Products - therapeutic use Bone marrow Bone Marrow Transplantation CD19 antigen Cell therapy Chemotherapy Chimeric antigen receptors Cytokines Drug Resistance, Neoplasm Female Genetics Genetics General Hematology Humans Immunotherapy Immunotherapy, Adoptive Leukemia Lymphocytes B Lymphocytes T Lymphoma Lymphoma, Large B-Cell, Diffuse - drug therapy Male Medical prognosis Middle Aged Oncology Progression-Free Survival Receptors, Chimeric Antigen - antagonists & inhibitors Statistical analysis Stem Cell Transplantation Transplantation, Autologous Treatments in Oncology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In a trial involving patients with relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to significantly longer event-free survival than standard salvage chemotherapy (which was followed by high-dose therapy and autologous stem-cell transplantation in patients with a response). High-grade toxic effects were common, but most patients recovered.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2116133